EUVIMEDEUVIMED entdecken
Crossref

Design and Synthesis of 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic Acid Derivatives as PP5 Inhibitors To Reverse Temozolomide Resistance in Glioblastoma Multiforme

Zekun Li, Mochen Guo, Mingxiao Gu, Zhongtian Cai, Qiuyu Wu, Jia Yu, Meilun Tang, Chenxi He, Yuxuan Wang, Piaoyang Sun, Qidong You iD, Lei Wang iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Zekun Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009…. Hauptthemen laut MEDLINE: Temozolomide, Drug Design, Drug Resistance, Neoplasm, Glioblastoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: China Association for Science and Technology, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The serine/threonine phosphatase family is important in tumor progression and survival. Due to the high conserved catalytic domain, designing selective inhibitors is challenging. Herein, we obtained compound 28a with 38-fold enhanced PP5 selectivity (PP2A/5 IC50 = 33.8/0.9 μM) and improved drug-like properties (favorable stability and safety, F = 82.0%) by rational drug design based on a phase II PP2A/5 dual target inhibitor LB-100. Importantly, we found the spatial conformational restriction of the 28a indole fragment was responsible for the selectivity of PP5. Thus, 28a activated p53 and downregulated cyclin D1 and MGMT, which showed potency in cell cycle arrest and reverse temozolomide (TMZ) resistance in the U87 MG cell line. Furthermore, oral administration of 28a and TMZ was well tolerated to effectively inhibit tumor growth (TGI = 87.7%) in the xenograft model. Collectively, these results implicate 28a could be a drug candidate by reversing TMZ resistance with a selective PP5 inhibition manner.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideDrug DesignDrug Resistance, NeoplasmGlioblastomaHumansAnimalsCell Line, TumorMiceStructure-Activity RelationshipMice, NudeAntineoplastic Agents, AlkylatingXenograft Model Antitumor AssaysCell ProliferationEnzyme Inhibitors

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingEnzyme Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
  • Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai 200245, China.

ORCID-Profile: Qidong You, Lei Wang

Förderung

  • China Association for Science and Technology
  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Li, Z., Guo, M., Gu, M., Cai, Z., Wu, Q., Yu, J., Tang, M., He, C., Wang, Y., Sun, P., You, Q., & Wang, L. (2024). Design and Synthesis of 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic Acid Derivatives as PP5 Inhibitors To Reverse Temozolomide Resistance in Glioblastoma Multiforme. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01304

Vancouver

Li Z, Guo M, Gu M, Cai Z, Wu Q, Yu J, et al. Design and Synthesis of 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic Acid Derivatives as PP5 Inhibitors To Reverse Temozolomide Resistance in Glioblastoma Multiforme. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01304

BibTeX
@article{Li2024,
  author = {Li, Zekun and Guo, Mochen and Gu, Mingxiao and Cai, Zhongtian and Wu, Qiuyu and Yu, Jia and Tang, Meilun and He, Chenxi and Wang, Yuxuan and Sun, Piaoyang and You, Qidong and Wang, Lei},
  title = {Design and Synthesis of 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic Acid Derivatives as PP5 Inhibitors To Reverse Temozolomide Resistance in Glioblastoma Multiforme},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01304}
}
Kostenlos starten →